COMMUNIQUÉS West-GlobeNewswire

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
21/11/2025
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/11/2025
NOVATO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
21/11/2025
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management [...]
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
21/11/2025
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference
21/11/2025
SYDNEY, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ), today announced that Dustin Haines, Chief Executive Officer, will participate in a fireside [...]
Inventiva reports 2025 Third Quarter Financial Information¹
21/11/2025
Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits 2 as of September 30, 2025. Revenues of €4.5 million for the first nine months of 2025. Cash runway expected until the end of the [...]
Inventiva publie ses informations financières du 3ème trimestre 2025¹
21/11/2025
Trésorerie et équivalents de trésorerie à 97,6 millions d’euros, et 24,7 millions d’euros en dépôts à court terme 2 au 30 septembre. Chiffre d’affaires de 4,5 millions d’euros sur les neuf premiers mois de 2025. Horizon [...]
Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.
21/11/2025
PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
TrialWire’s™ Industry Leading AI-powered Patient Recruitment Platform Delivers Continuous Clinical Trial Referrals over Holiday Season
21/11/2025
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- TrialWire ™, the industry’s fastest, advanced AI-powered, algorithm-driven patient recruitment platform, today announced its RapidStart™ and RapidRescue™ solutions are [...]
Brain Injury Association of America Honored Centre for Neuro Skills’ Dr. Mark Ashley as Luminary of the Year
21/11/2025
BAKERSFIELD, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- The Brain Injury Association of America (BIAA) honored Dr. Mark J. Ashley, Founder and Executive Chairman of the Board of Centre for Neuro Skills (CNS), as Luminary [...]
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
21/11/2025
-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved [...]
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
21/11/2025
TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of [...]
Sharecare wins 22 Digital Health Awards in Fall 2025 competition
21/11/2025
Company earns five Golds for its NCQA-accredited health navigation platform, Diabetes Prevention Program, and patient education and engagement solutions ATLANTA, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sharecare, the digital [...]
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
21/11/2025
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA [...]
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21/11/2025
MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation
21/11/2025
NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
21/11/2025
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an [...]
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
21/11/2025
RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request [...]
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
21/11/2025
90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatment Study will run approximately 12 months and enroll up to 100 patients Internal estimates of the [...]

Pages